BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/19/2020 4:08:52 PM | Browse: 533 | Download: 1276
 |
Received |
|
2020-09-08 09:49 |
|
Peer-Review Started |
|
2020-09-08 09:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-24 19:30 |
|
Revised |
|
2020-10-08 08:41 |
|
Second Decision |
|
2020-10-29 10:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-02 04:18 |
|
Articles in Press |
|
2020-11-02 04:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-11-12 04:00 |
|
Typeset the Manuscript |
|
2020-11-30 04:55 |
|
Publish the Manuscript Online |
|
2020-12-19 16:08 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Prospective Study |
| Article Title |
Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mao-Hui Yan, Xiao-Bin Hou, Bo-Ning Cai, Bao-Lin Qu, Xiang-Kun Dai and Fang Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fang Liu, MD, Chief Doctor, Department of Radiotherapy, the First Medical Center of the Chinese PLA General Hospital, No. 28 Fuxing Road , Beijing 100853, China. liufangfsg@163.com |
| Key Words |
Esophageal cancer; Neoadjuvant chemoradiotherapy; Surgical treatment; Radiotherapy; Chemotherapy; Toxicity |
| Core Tip |
Esophageal cancer is one of the most common malignant tumors of digestive system worldwide, with an estimated 572000 new cases and 509000 deaths annually. Treatments for locally advanced esophageal cancer include surgery and radical chemoradiotherapy. Although surgery is one of the mainstream treatments for esophageal cancer, the efficacy of surgery alone is poor. In recent years, neoadjuvant chemoradiotherapy combined with surgery has been gradually applied in patients with locally advanced thoracic esophageal cancer, but its effectiveness and safety remains unclear. In this clinical trial, we prospectively investigated the efficacy and safety of neoadjuvant chemoradiotherapy plus surgery in the treatment of thoracic esophageal squamous cell carcinoma. |
| Publish Date |
2020-12-19 16:08 |
| Citation |
Yan MH, Hou XB, Cai BN, Qu BL, Dai XK, Liu F. Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma. World J Clin Cases 2020; 8(24): 6315-6321 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i24/6315.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i24.6315 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
